JP7649624B2 - 副甲状腺ホルモン受容体刺激を介する、骨折をターゲティングした骨再生 - Google Patents

副甲状腺ホルモン受容体刺激を介する、骨折をターゲティングした骨再生 Download PDF

Info

Publication number
JP7649624B2
JP7649624B2 JP2019529240A JP2019529240A JP7649624B2 JP 7649624 B2 JP7649624 B2 JP 7649624B2 JP 2019529240 A JP2019529240 A JP 2019529240A JP 2019529240 A JP2019529240 A JP 2019529240A JP 7649624 B2 JP7649624 B2 JP 7649624B2
Authority
JP
Japan
Prior art keywords
seq
bone
compound
conjugated
polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019529240A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020500871A5 (https=
JP2020500871A (ja
Inventor
エス． ロウ，フィリップ
エー． ロウ，スチュアート
ジェイ ハワード ニールセン，ジェフリー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Purdue Research Foundation
Original Assignee
Purdue Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Purdue Research Foundation filed Critical Purdue Research Foundation
Publication of JP2020500871A publication Critical patent/JP2020500871A/ja
Publication of JP2020500871A5 publication Critical patent/JP2020500871A5/ja
Priority to JP2022193738A priority Critical patent/JP2023029957A/ja
Application granted granted Critical
Publication of JP7649624B2 publication Critical patent/JP7649624B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/29—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/548—Phosphates or phosphonates, e.g. bone-seeking
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0031—Rectum, anus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/635—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2019529240A 2016-11-30 2017-11-30 副甲状腺ホルモン受容体刺激を介する、骨折をターゲティングした骨再生 Active JP7649624B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022193738A JP2023029957A (ja) 2016-11-30 2022-12-02 副甲状腺ホルモン受容体刺激を介する、骨折をターゲティングした骨再生

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662428492P 2016-11-30 2016-11-30
US62/428,492 2016-11-30
US201762553313P 2017-09-01 2017-09-01
US62/553,313 2017-09-01
PCT/US2017/064081 WO2018102616A1 (en) 2016-11-30 2017-11-30 Fracture targeted bone regeneration through parathyroid hormone receptor stimulation

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022193738A Division JP2023029957A (ja) 2016-11-30 2022-12-02 副甲状腺ホルモン受容体刺激を介する、骨折をターゲティングした骨再生

Publications (3)

Publication Number Publication Date
JP2020500871A JP2020500871A (ja) 2020-01-16
JP2020500871A5 JP2020500871A5 (https=) 2021-01-21
JP7649624B2 true JP7649624B2 (ja) 2025-03-21

Family

ID=62241919

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019529240A Active JP7649624B2 (ja) 2016-11-30 2017-11-30 副甲状腺ホルモン受容体刺激を介する、骨折をターゲティングした骨再生
JP2022193738A Pending JP2023029957A (ja) 2016-11-30 2022-12-02 副甲状腺ホルモン受容体刺激を介する、骨折をターゲティングした骨再生

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022193738A Pending JP2023029957A (ja) 2016-11-30 2022-12-02 副甲状腺ホルモン受容体刺激を介する、骨折をターゲティングした骨再生

Country Status (10)

Country Link
US (3) US20200317745A1 (https=)
EP (1) EP3548012A4 (https=)
JP (2) JP7649624B2 (https=)
CN (1) CN110114065A (https=)
AU (1) AU2017367699B2 (https=)
BR (1) BR112019011070A2 (https=)
CA (1) CA3045458A1 (https=)
IL (1) IL266977B2 (https=)
MX (1) MX2019006189A (https=)
WO (1) WO2018102616A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018102616A1 (en) * 2016-11-30 2018-06-07 Purdue Research Foundation Fracture targeted bone regeneration through parathyroid hormone receptor stimulation
WO2019232285A1 (en) 2018-05-30 2019-12-05 Purdue Research Foundation Targeting anabolic drugs for accelerated fracture repair
CN110551201B (zh) * 2019-08-26 2020-04-28 杭州彗搏科技有限公司 一种新型骨形成蛋白2来源的环肽、制备方法及其应用
MX2022002979A (es) * 2019-09-12 2022-06-16 Radius Health Inc Metodos para mejorar la fusion vertebral con abaloparatida.
CN112646042A (zh) * 2019-10-10 2021-04-13 陕西麦科奥特科技有限公司 活性多肽化合物
AU2021338361A1 (en) * 2020-09-03 2023-04-06 Chen, Irvin S.Y Soluble alkaline phosphatase constructs and expression vectors including a polynucleotide encoding for soluble alkaline phosphatase constructs
WO2022093373A1 (en) * 2020-10-26 2022-05-05 Purdue Research Foundation Compounds,compositions and methods of use to treat bone fractures
WO2022093374A1 (en) * 2020-10-26 2022-05-05 Purdue Research Foundation Compounds,compositions and methods of use to treat spinal fusions
AU2022205801A1 (en) * 2021-01-05 2023-07-13 Radius Health, Inc. Treatment of long bone fractures with abaloparatide
US20250295725A1 (en) * 2022-01-14 2025-09-25 Purdue Research Foundation Bone targeted treatment in osteogenesis imperfecta
EP4719459A1 (en) * 2023-06-01 2026-04-08 Radius Health, Inc. Methods for identification and quantitation of abaloparatide and related peptide impurities
WO2025019691A1 (en) * 2023-07-19 2025-01-23 Zymeron Corporation Drug conjugates for bone marrow protection

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000327583A (ja) 1999-05-17 2000-11-28 Medei Sci Puraningu:Kk 骨指向性ホルモン誘導体
JP2007533669A (ja) 2004-04-21 2007-11-22 エノビア ファーマ インコーポレイティド 骨送達複合体ならびにタンパク質に骨を標的化させるためのその使用方法
JP2008501307A (ja) 2004-06-10 2008-01-24 俊治 戸松 酸性アミノ酸からなる短鎖ペプチドを付加したタンパク質
JP2010505835A (ja) 2006-10-03 2010-02-25 ラジウス ヘルス，インコーポレイテッド 骨同化作用を有するタンパク質のための薬物送達方法
JP2010523671A (ja) 2007-04-09 2010-07-15 ザ ボード オブ トラスティーズ オブ ザ ユニバーシティ オブ アーカンソー コラーゲン結合領域と副甲状腺ホルモンとの融合タンパク
JP2010526543A (ja) 2007-05-11 2010-08-05 エノビア ファルマ インコーポレイテッド 骨標的アルカリホスファターゼ、キット及びその使用方法
WO2012111852A1 (ja) 2011-02-17 2012-08-23 帝人ファーマ株式会社 椎体骨折治療剤及びその評価方法
JP2014517825A (ja) 2011-04-22 2014-07-24 ラジウス ヘルス，インコーポレイテッド ＰＴＨ、ＰＴＨｒＰ、および関連ペプチドの薬剤送達方法
US20140378382A1 (en) 2013-06-23 2014-12-25 Massachusetts General Hospital Alpha-/beta-polypeptide analogs of parathyroid hormone (pth) and method of using same
US20150246957A1 (en) 2012-08-28 2015-09-03 The Governors Of The University Of Alberta Parathyroid hormone, insulin, and related peptides conjugated to bone targeting moieties and methods and making and using thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU9103791A (en) * 1990-12-21 1992-07-22 Allelix Biopharmaceuticals Inc. Oxidation resistant variants of parathyroid hormone
WO1995002610A1 (en) * 1993-07-13 1995-01-26 Syntex (U.S.A.) Inc. Analogs of parathyroid hormone and parathyroid hormone related peptide: synthesis and use for the treatment of osteoporosis
JP4394279B2 (ja) * 1998-03-09 2010-01-06 ジーランド ファーマ アクティーゼルスカブ 酵素加水分解に対する傾向が減少した薬理学的に活性なペプチド複合体
US7057012B1 (en) * 1998-12-31 2006-06-06 The General Hospital Corporation PTH functional domain conjugate peptides, derivatives thereof and novel tethered ligand-receptor molecules
WO2004062588A2 (en) * 2003-01-06 2004-07-29 University Of Utah Water-soluble polymeric bone-targeting drug delivery system
US20110046059A1 (en) * 2005-09-06 2011-02-24 Zelos Therapeutics, Inc. Pharmaceutically acceptable formulations/compositions for peptidyl drugs
US7803770B2 (en) * 2006-10-03 2010-09-28 Radius Health, Inc. Method of treating osteoporosis comprising administration of PTHrP analog
EP2303288A4 (en) * 2008-05-22 2015-04-22 Univ Ramot CONJUGATES OF A POLYMER, A BISPHOSPHONATE AND AN ANTI-ANGIOGENESE MEDIUM AND ITS USE IN THE TREATMENT AND CONTROL OF ILLNESSES RELATED TO BONE
CN102824647B (zh) * 2011-06-13 2014-07-23 香港中文大学 基于小核酸药物成骨治疗的骨靶向递送系统及其制备方法
CA2977812A1 (en) * 2015-03-03 2016-09-09 Radius Health, Inc. Uses of pthrp analogue in reducing fracture risk
WO2016196400A1 (en) * 2015-05-29 2016-12-08 Purdue Research Foundation Bone fracture repair by targeting of agents that promote bone healing
CN106039316B (zh) * 2016-05-03 2019-04-02 同济大学 一种基于多肽构建的成骨细胞靶向载体及其制备与应用
WO2018102616A1 (en) * 2016-11-30 2018-06-07 Purdue Research Foundation Fracture targeted bone regeneration through parathyroid hormone receptor stimulation
WO2022093373A1 (en) * 2020-10-26 2022-05-05 Purdue Research Foundation Compounds,compositions and methods of use to treat bone fractures

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000327583A (ja) 1999-05-17 2000-11-28 Medei Sci Puraningu:Kk 骨指向性ホルモン誘導体
JP2007533669A (ja) 2004-04-21 2007-11-22 エノビア ファーマ インコーポレイティド 骨送達複合体ならびにタンパク質に骨を標的化させるためのその使用方法
JP2008501307A (ja) 2004-06-10 2008-01-24 俊治 戸松 酸性アミノ酸からなる短鎖ペプチドを付加したタンパク質
JP2010505835A (ja) 2006-10-03 2010-02-25 ラジウス ヘルス，インコーポレイテッド 骨同化作用を有するタンパク質のための薬物送達方法
JP2010523671A (ja) 2007-04-09 2010-07-15 ザ ボード オブ トラスティーズ オブ ザ ユニバーシティ オブ アーカンソー コラーゲン結合領域と副甲状腺ホルモンとの融合タンパク
JP2010526543A (ja) 2007-05-11 2010-08-05 エノビア ファルマ インコーポレイテッド 骨標的アルカリホスファターゼ、キット及びその使用方法
WO2012111852A1 (ja) 2011-02-17 2012-08-23 帝人ファーマ株式会社 椎体骨折治療剤及びその評価方法
JP2014517825A (ja) 2011-04-22 2014-07-24 ラジウス ヘルス，インコーポレイテッド ＰＴＨ、ＰＴＨｒＰ、および関連ペプチドの薬剤送達方法
US20150246957A1 (en) 2012-08-28 2015-09-03 The Governors Of The University Of Alberta Parathyroid hormone, insulin, and related peptides conjugated to bone targeting moieties and methods and making and using thereof
US20140378382A1 (en) 2013-06-23 2014-12-25 Massachusetts General Hospital Alpha-/beta-polypeptide analogs of parathyroid hormone (pth) and method of using same

Also Published As

Publication number Publication date
JP2023029957A (ja) 2023-03-07
IL266977B1 (en) 2023-09-01
AU2017367699B2 (en) 2023-12-07
WO2018102616A1 (en) 2018-06-07
AU2017367699A8 (en) 2019-07-25
US10960054B2 (en) 2021-03-30
IL266977B2 (en) 2024-01-01
MX2019006189A (es) 2019-11-18
AU2017367699A1 (en) 2019-07-11
EP3548012A1 (en) 2019-10-09
JP2020500871A (ja) 2020-01-16
RU2019119701A3 (https=) 2021-02-16
CA3045458A1 (en) 2018-06-07
US20200317745A1 (en) 2020-10-08
CN110114065A (zh) 2019-08-09
US20210283227A1 (en) 2021-09-16
IL266977A (en) 2019-07-31
BR112019011070A2 (pt) 2019-10-01
RU2019119701A (ru) 2021-01-14
EP3548012A4 (en) 2020-07-22
US20200316174A1 (en) 2020-10-08

Similar Documents

Publication Publication Date Title
JP7649624B2 (ja) 副甲状腺ホルモン受容体刺激を介する、骨折をターゲティングした骨再生
JP2004500838A (ja) 副甲状腺ホルモンおよび副甲状腺ホルモン関連タンパク質アンタゴニスト
JPH07500315A (ja) 骨成長因子の標的送達
JP2000516579A (ja) 腸栄養性ｇｌｐ―２ペプチドのアンタゴニスト
JP4334480B2 (ja) α−ヘリックス安定化剤を用いる高次構造的に制約された副甲状腺ホルモン
JP5360738B2 (ja) 細胞増殖促進活性を有するペプチド
JP2024506435A (ja) 化合物、組成物、および骨折を処置するための使用方法
KR101108354B1 (ko) Ｐｔｈ 수용체 조절제로서의 페길화된 ｐｔｈ 및 그의 용도
US20230390363A1 (en) Compounds, Compositions and Methods of Use to Treat Spinal Fusions
US7132394B2 (en) PTH-like peptides
JP5529014B2 (ja) 部位特異的なペグ化をされた直鎖状のサケカルシトニン類似体
RU2785401C2 (ru) Направленная регенерация переломанной кости посредством стимуляции рецептора паратиреоидного гормона
US20090042802A1 (en) Compounds and peptides that bind the kgf receptor
CN116801900A (zh) 用于治疗骨折的化合物、组合物和使用方法
CN116710068A (zh) 用于治疗脊柱融合的化合物、组合物和方法
US7399826B1 (en) Peptide for promoting healing of fractures
KR20210082120A (ko) Glp-2 또는 이의 결합체를 포함하는 골 대사성 질환에 대한 예방 또는 치료용 약학적 조성물
HK40050388B (zh) 用於激活骨祖细胞中细胞信号传导的肽
JPH08176191A (ja) 合成ペプチド誘導体または、その塩
TW200817439A (en) PTH receptor modulators and uses thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201127

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20201127

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20210922

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20211005

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220105

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220303

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220404

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20220802

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20221128

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20221202

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221208

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20221216

C116 Written invitation by the chief administrative judge to file amendments

Free format text: JAPANESE INTERMEDIATE CODE: C116

Effective date: 20230123

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20230123

C092 Termination of reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C092

Effective date: 20230124

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241128

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250310

R150 Certificate of patent or registration of utility model

Ref document number: 7649624

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150